The applicability of c-MYC as a marker for a dismal prognosis of pancreatic cancer has also been validated and can be attributed, in part, to elevated expression of this transcription factor in the basal subtype of PDAC that lacks GATA6 [36–39]. This evidence concerns the gene MYC and pancreatic neoplasm.